You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思(01167.HK)回升13%成交增 自主研發新藥獲國家藥監局准臨床實驗
阿思達克 05-28 10:32
加科思-B(01167.HK)自主研發新藥獲國家藥監局批准進行臨床實驗,該股整固守穩20天線,今早曾急漲16%至24.25元,現造23.55元,急漲13%,一向薄弱成交增至111萬股,涉資2,594萬元。

加科思公布,公司自主研發的JAB-21822項目KRAS G12C抑制劑的新藥臨床試驗申請已於5月27日獲得國家藥品監督管理局藥品審評中心批准,此前該項目IND已獲得美國FDA批准。該新藥將用於治療KRAS G12C突變的晚期實體瘤,包括但不限於非小細胞肺癌(NSCLC)及結直腸癌(CRC)等晚期實體瘤。

加科思是一家仍處於臨床階段製藥公司,專注於創新腫瘤療法自主研發。股份於去年12月中旬以每股14元在港上市,淨籌12.63億元,主要用作產品的臨床開發和商業化。掛牌後,股價曾於上市首周反覆低見13元獲承接回升,並於今年2月初曾升至25.35元上市新高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account